GlassScriptPhysician profile
Maggie Tavdy
NPI 1750470837
$24,772.86
in general payments reported to CMS, 2019-2025
53 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,422 · 2020: $7,306 · 2021: $1,925 · 2022: $2,237 · 2023: $2,060 · 2024: $2,018 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,817.76 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,109.50 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $1,593.09 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,179.31 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $1,005.02 | 2019-2025 | Synthroid, Botox, Ubrelvy |
| Lilly USA, LLC | $811.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $665.60 | 2019-2022 | |
| Medtronic, INC. | $526.73 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Amneal Pharmaceuticals LLC | $476.57 | 2022-2025 | Unithroid |
| Mannkind Corporation | $457.95 | 2019-2024 | Afrezza, V-Go |
| Cequr Corporation | $384.17 | 2022-2025 | Cequr Simplicity |
| Abbott Laboratories | $383.14 | 2020-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $310.06 | 2021-2023 | |
| Intuity Medical INC | $278.88 | 2022 | |
| Merck Sharp & Dohme LLC | $202.51 | 2019-2021 | |
| Corcept Therapeutics | $188.50 | 2019-2025 | Korlym |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Tavdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.